Neurology Clinical Trials Market Report 2023-2033

Neurology Clinical Trials Market Report 2023-2033



The Neurology Clinical Trials Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The implementation of wearable devices, mobile health applications, and remote monitoring tools has brought about a significant paradigm shift in data collection by facilitating the instantaneous monitoring of patient outcomes and the advancement of diseases. These technologies furnish an abundance of ongoing, unbiased data, thereby augmenting the accuracy and dependability of trial outcomes. In addition, developments in neuroimaging methodologies, including functional MRI and PET scans, provide unparalleled perspectives on the operation and interconnections of the brain. The incorporation of technology into the trial process not only enhances efficiency but also provides novel opportunities for comprehending neurological disorders.

What Questions Should You Ask before Buying a Market Research Report?
  • How is the neurology clinical trials market evolving?
  • What is driving and restraining the neurology clinical trials market?
  • How will each neurology clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each neurology clinical trials submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading neurology clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the neurology clinical trials projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of
neurology clinical trials projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the neurology clinical trials market?
  • Where is the neurology clinical trials market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the neurology clinical trials market today, and over the next 10 years:
  • Our 262-page report provides 107 tables and 153 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the neurology clinical trials market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Study Design
  • Interventional
  • Observational
  • Expanded Access
Indication
  • Epilepsy
  • Stroke
  • Alzheimer’s Disease (AD)
  • Parkinson’s Disease (PD)
  • Traumatic Brain Injury (TBI)
  • Others
Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America
  • U.S.
  • Canada
Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
MEA
  • GCC
  • South Africa
  • Rest of MEA
The report also includes profiles and for some of the leading companies in the Neurology Clinical Trials Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
  • AbbVie Inc.
  • Alector, Inc.
  • Annovis Bio
  • AstraZeneca
  • Athira Pharma, Inc.
  • Biogen
  • Charles River Laboratories
  • Eisai Inc.
  • Eli Lilly and Company
  • ICON plc
  • IQVIA
  • Laboratory Drug Development
  • Medpace Holdings, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Supernus Pharmaceuticals, Inc.
  • Syneos Health
  • Teva Pharmaceutical Industries Ltd.
Overall world revenue for Neurology Clinical Trials Market, 2023 to 2033 in terms of value the market will surpass US$9,600 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Neurology Clinical Trials Market, 2023 to 2033 report help you?

In summary, our 260+ page report provides you with the following knowledge:
  • Revenue forecasts to 2033 for Neurology Clinical Trials Market 2023 to 2033, with forecasts for study design, indication, and phase, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 20 key national markets – See forecasts for the Neurology Clinical Trials Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for 19 of the major companies involved in the Neurology Clinical Trials Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Neurology Clinical Trials Market 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.


1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Neurology Clinical Trials Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Prevalence of Neurological Disorders
3.2.1.2 Growing Adoption of Novel Technologies in Clinical Research
3.2.1.3 Significant Number of CROs Providing Neurology Clinical Research Services
3.2.1.4 Increasing Funding for Neurological Studies
3.2.2 Market Restraining Factors
3.2.2.1 High Cost Associated with Neurology Clinical Studies
3.2.2.2 High Failure Rate and Patient Dropout Issues
3.2.3 Market Opportunities
3.2.3.1 Aging Population Projected to Offer Lucrative Growth Prospects
3.2.3.2 Personalised Medicine and Biomarker Development in Clinical Trials
3.2.3.3 Artificial Intelligence and Machine Learning in Neurology Clinical Trials
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
4 Neurology Clinical Trials Market Analysis by Study Design
4.1 Key Findings
4.2 Study Design Segment: Market Attractiveness Index
4.3 Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
4.4 Interventional
4.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Observational
4.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Expanded Access
4.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
4.6.2 Market Share by Region, 2023 & 2033 (%)
5 Neurology Clinical Trials Market Analysis by Indication
5.1 Key Findings
5.2 Indication Segment: Market Attractiveness Index
5.3 Neurology Clinical Trials Market Size Estimation and Forecast by Indication
5.4 Epilepsy
5.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Stroke
5.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Alzheimer’s Disease (AD)
5.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Parkinson’s Disease (PD)
5.7.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.7.2 Market Share by Region, 2023 & 2033 (%)
5.8 Traumatic Brain Injury (TBI)
5.8.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.8.2 Market Share by Region, 2023 & 2033 (%)
5.9 Others
5.9.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.9.2 Market Share by Region, 2023 & 2033 (%)
6 Neurology Clinical Trials Market Analysis by Phase
6.1 Key Findings
6.2 Phase Segment: Market Attractiveness Index
6.3 Neurology Clinical Trials Market Size Estimation and Forecast by Phase
6.4 Phase I
6.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Phase II
6.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Phase III
6.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
6.6.2 Market Share by Region, 2023 & 2033 (%)
6.7 Phase IV
6.7.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
6.7.2 Market Share by Region, 2023 & 2033 (%)
7 Neurology Clinical Trials Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
8 North America Neurology Clinical Trials Market Analysis
8.1 Key Findings
8.2 North America Neurology Clinical Trials Market Attractiveness Index
8.3 North America Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
8.4 North America Neurology Clinical Trials Market Size Estimation and Forecast by Country
8.5 North America Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
8.6 North America Neurology Clinical Trials Market Size Estimation and Forecast by Indication
8.7 North America Neurology Clinical Trials Market Size Estimation and Forecast by Phase
8.8 U.S. Neurology Clinical Trials Market Analysis
8.9 Canada Neurology Clinical Trials Market Analysis
9 Europe Neurology Clinical Trials Market Analysis
9.1 Key Findings
9.2 Europe Neurology Clinical Trials Market Attractiveness Index
9.3 Europe Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
9.4 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Country
9.5 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
9.6 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Indication
9.7 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Phase
9.8 Germany Neurology Clinical Trials Market Analysis
9.9 UK Neurology Clinical Trials Market Analysis
9.10 France Neurology Clinical Trials Market Analysis
9.11 Italy Neurology Clinical Trials Market Analysis
9.12 Spain Neurology Clinical Trials Market Analysis
9.13 Rest of Europe Neurology Clinical Trials Market Analysis
10 Asia Pacific Neurology Clinical Trials Market Analysis
10.1 Key Findings
10.2 Asia Pacific Neurology Clinical Trials Market Attractiveness Index
10.3 Asia Pacific Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
10.4 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Country
10.5 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
10.6 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Indication
10.7 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Phase
10.8 Japan Neurology Clinical Trials Market Analysis
10.9 China Neurology Clinical Trials Market Analysis
10.10 India Neurology Clinical Trials Market Analysis
10.11 Australia Neurology Clinical Trials Market Analysis
10.12 South Korea Neurology Clinical Trials Market Analysis
10.13 Rest of Asia Pacific Neurology Clinical Trials Market Analysis
11 Latin America Neurology Clinical Trials Market Analysis
11.1 Key Findings
11.2 Latin America Neurology Clinical Trials Market Attractiveness Index
11.3 Latin America Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
11.4 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Country
11.5 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
11.6 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Indication
11.7 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Phase
11.8 Brazil Neurology Clinical Trials Market Analysis
11.9 Mexico Neurology Clinical Trials Market Analysis
11.10 Rest of Latin America Neurology Clinical Trials Market Analysis
12 MEA Neurology Clinical Trials Market Analysis
12.1 Key Findings
12.2 MEA Neurology Clinical Trials Market Attractiveness Index
12.3 MEA Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
12.4 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Country
12.5 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
12.6 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Indication
12.7 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Phase
12.8 GCC Neurology Clinical Trials Market Analysis
12.9 South Africa Neurology Clinical Trials Market Analysis
12.10 Rest of MEA Neurology Clinical Trials Market Analysis
13 Company Profiles
13.1 Biogen
13.1.1 Company Snapshot
13.1.2 Company Overview
13.1.3 Financial Analysis
13.1.3.1 Net Revenue, 2015-2022
13.1.3.2 R&D, 2015-2022
13.1.4 Product Benchmarking
13.1.5 Strategic Outlook
13.2 AbbVie Inc.
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2015-2022
13.2.3.2 Regional Market Shares, 2022
13.2.3.3 R&D, 2015-2022
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 Sanofi
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2015-2022
13.3.3.2 Regional Market Shares, 2022
13.3.3.3 R&D, 2015-2022
13.3.4 Product Benchmarking
13.4 Teva Pharmaceutical Industries Ltd.
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2015-2022
13.4.3.2 Regional Market Shares, 2022
13.4.3.3 R&D, 2015-2022
13.4.4 Product Benchmarking
13.5 Eli Lilly and Company
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2015-2022
13.5.3.2 R&D, 2015-2022
13.5.4 Product Benchmarking
13.5.5 Strategic Outlook
13.6 Merck & Co., Inc.
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2015-2022
13.6.3.2 Regional Market Shares, 2022
13.6.3.3 R&D, 2015-2022
13.6.4 Product Benchmarking
13.7 Eisai Inc.
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2015-2022
13.7.3.2 R&D, 2015-2022
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 AstraZeneca
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis
13.8.3.1 Net Revenue, 2015-2022
13.8.3.2 Regional Market Shares, 2022
13.8.3.3 R&D, 2015-2022
13.8.4 Product Benchmarking
13.9 Charles River Laboratories
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2015-2022
13.9.3.2 Regional Market Shares, 2022
13.9.4 Product Benchmarking
13.10 Alector, Inc.
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Product Benchmarking
13.10.4 Strategic Outlook
13.11 ICON plc
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2015-2022
13.11.3.2 Regional Market Shares, 2022
13.11.4 Product Benchmarking
13.11.5 Strategic Outlook
13.12 IQVIA
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2015-2022
13.12.3.2 Regional Market Shares, 2022
13.12.4 Product Benchmarking
13.12.5 Strategic Outlook
13.13 Labcorp Drug Development
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis
13.13.3.1 Net Revenue, 2015-2022
13.13.4 Product Benchmarking
13.13.5 Strategic Outlook
13.14 Medpace Holdings, Inc.
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis
13.14.3.1 Net Revenue, 2015-2022
13.14.4 Product Benchmarking
13.15 Novartis AG
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Analysis
13.15.3.1 Net Revenue, 2015-2022
13.15.3.2 Regional Market Shares, 2022
13.15.3.3 R&D, 2015-2022
13.15.4 Product Benchmarking
13.15.5 Strategic Outlook
13.16 Syneos Health
13.16.1 Company Snapshot
13.16.2 Company Overview
13.16.3 Financial Analysis
13.16.3.1 Net Revenue, 2015-2022
13.16.3.2 Regional Market Shares, 2022
13.16.4 Product Benchmarking
13.16.5 Strategic Outlook
13.17 Annovis Bio
13.17.1 Company Snapshot
13.17.2 Company Overview
13.17.3 Product Benchmarking
13.17.4 Strategic Outlook
13.18 Supernus Pharmaceuticals, Inc.
13.18.1 Company Snapshot
13.18.2 Company Overview
13.18.3 Product Benchmarking
13.19 Athira Pharma, Inc.
13.19.1 Company Snapshot
13.19.2 Company Overview
13.19.3 Product Benchmarking
14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings